Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of VNX001 Compared to Placebo, and the Individual Components of Lidocaine, and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity; The Engage 2024 Study

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and its individual components (heparin sodium and lidocaine hydrochloride (HCl)) for the reduction of bladder pain in patients with interstitial cystitis (IC) / bladder pain syndrome (BPS), Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity.

Study Overview

• Status: Recruiting
• Conditions: Interstitial Cystitis; Bladder Pain Syndrome
• Intervention / Treatment: Drug: VNX001; Drug: Placebo; Drug: Lidocaine; Drug: Heparin

Detailed Description

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and its individual components (heparin sodium and lidocaine hydrochloride) for the reduction of bladder pain in patients with IC/BPS, Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity. The study will enroll a target of 120 subjects, with a maximum of 180 subjects, across approximately 12 sites in the United States. Each study subject will receive a single dose of VNX001, placebo (alkalinized phosphate buffer), alkalinized lidocaine, or alkalinized heparin by random assignment. The randomization ratio will be 3:1:3:1, respectively. At 24-48-hours post-dose, all subjects will be given the option of requesting a single dose of VNX001.

• Study Type: Interventional
• Enrollment (Estimated): 120
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Vaneltix Pharma, Inc.; Phone Number: 732-354-3217; Email: info@vaneltix.com

Study Locations

• United States
  • California
    • Escondido, California, United States, 92025
      • Suspended
      • IC Study LLC
    • Los Angeles, California, United States, 90095
      • Completed
      • University of California Los Angeles Center for Women's Pelvic Health
    • Newport Beach, California, United States, 92663
      • Recruiting
      • The Clark Center for Urogynecology
    • Newport Beach, California, United States, 92663
      • Completed
      • The Continence Center Medical Group, Inc dba Southern California Continence Center
    • San Diego, California, United States, 92103
      • Recruiting
      • University of California San Diego Medical Center
    • Tustin, California, United States, 92780
      • Recruiting
      • Prestige Medical Group
  • Florida
    • Hialeah, Florida, United States, 33012
      • Recruiting
      • United Research Institute
    • Tampa, Florida, United States, 33615
      • Recruiting
      • Florida Urology Partners
  • Georgia
    • Cartersville, Georgia, United States, 30120
      • Recruiting
      • Georgia Urology
  • Louisiana
    • Metairie, Louisiana, United States, 70001
      • Recruiting
      • Southern Clinical Research Associates LLC
  • Massachusetts
    • Watertown, Massachusetts, United States, 02472
      • Recruiting
      • Bay State Clinical Trials
  • Nevada
    • Las Vegas, Nevada, United States, 89144
      • Recruiting
      • Sheldon Freedman MD LTD
  • New York
    • Lake Success, New York, United States, 11042
      • Recruiting
      • Northwell Health
  • North Carolina
    • Winston-Salem, North Carolina, United States, 27101
      • Recruiting
      • The Wake Forest Institute of Regenerative Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Be able and willing to give a signed informed consent and to follow study instructions
• Be male or female, ≥ 18 years of age
• Have a history of IC/BPS for at least 9 months prior to the study
• Have a score of ≥ 16 and ≤ 30 on the Pelvic Pain and Urgency/Frequency (PUF) questionnaire, completed at screening
• Have an episode of acute bladder pain of moderate to severe intensity with a minimum score of 5 on the 11-point bladder pain NRS at time of screening and 15 minutes post void immediately prior to study drug administration.
• Have previously received a therapeutic intravesicular anesthetic treatment according to medication history

Exclusion Criteria:

• For females, have a positive pregnancy test at screening or be pregnant or lactating
• Males who are sexually active with females and are not willing to commit to an acceptable method of birth control for the duration of the
• Postmenopausal women who, if taking hormone replacement therapy, have not been stabilized on a regimen of hormone replacement therapy within 3 months of screening
• Have a known hypersensitivity to heparin or lidocaine
• Have used any local anesthetic by any route within 48-hours prior to study drug administration, or used a lidocaine patch or lidocaine containing topical compounds within 14 days prior to study drug administration
• Have used a tricyclic antidepressant, or a gamma-aminobutyric acid (GABA) analogue (gabapentin or pregabalin), unless taking a stable dose of the medication for ≥ 3 weeks. The stable dose of gabapentin may not exceed 1,200 mg per day, and the stable dose of pregabalin may not exceed 150 mg per day
• Have used any pain medication within 6 hours prior to study drug administration
• Have used narcotics or medical marijuana ≤ 3 weeks prior to study entry
• Have used prohibited drugs as determined by self-report, positive urine drug screen, or in the opinion of the investigator be under the influence of drugs affecting mentation precluding their ability to follow the study protocol or bias study results
• Have a known abnormal laboratory test value that, in the investigator's judgement, is clinically significant.
• Have a neurogenic bladder or other disorder that, in the opinion of the investigator, may cause neurogenic bladder (including Parkinson's disease, multiple sclerosis, epilepsy, myasthenia gravis, movement disorders, spinal cord damage)
• Have pain or a pain disorder that, in the opinion of the investigator, would make it difficult to discriminate pelvic pain of bladder origin from the other pain
• Have any of the following central nervous system (CNS) conditions that in the opinion of the investigator would impact the subject's study participation due to their ability to follow the study protocol or bias study results, severe diagnosed: major depressive disorder, bipolar disorder, schizophrenia, general anxiety disorder, attention deficit disorder, obsessive compulsive disorder, or other major central nervous system disorder
• Have history of arrhythmias, conduction disturbances, or cardiac disease, or any coexisting medical condition that, in the opinion of the investigator, may be significant or interfere with study procedures or interpretation of study results
• Had anesthetic bladder instillation therapy within 14 days prior to study entry
• Had an in-office cystoscopy within 7 days of study drug administration
• Had dilatation (hydrodistension) of bladder within 3 months of study entry
• Evidence or suspected presence of cancer detected during cystoscopy 7 days prior to or at time of initial screening
• Has received any investigational drug or device within 30 days prior to screening
• Is currently enrolled in another investigational drug or device study
• Is unwilling or unable to abide by the requirements of the study
• Have an actively bleeding lesion or area in the bladder as detected by dipstick urinalysis and investigator assessment, immediately prior to randomization
• Have a history of coagulopathy or taking anticoagulants.
• Are taking any of the following medications, which are inducers of CYP1A2 and/or CYP3A4: Phenytoin, Carbamazepine, St. John's Wort, Phenobarbital, Rifampin

• Have had any of the following:

  • Bacterial cystitis within 30 days as demonstrated by a positive urine culture (≥ 105 bacteria per mL)
  • History of pelvic irradiation or radiation cystitis
  • History or presence of uterine, cervical, pelvic, rectal, ovarian, or vaginal cancer
  • History of benign or malignant bladder tumors
  • Current chemotherapy
  • History or presence of tuberculous cystitis
  • History or presence of chemical cystitis, including that due to cyclophosphamide
  • History or presence of urinary schistosomiasis
  • Bladder or ureteral calculi
  • Clinically significant infectious vaginitis
  • Currently uncontrolled genital herpes
  • History or presence of urethral diverticulum
  • Presence of bladder fistulae
  • History of ketamine use

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: VNX001; VNX001 (lidocaine HCl [200 mg] and heparin sodium [50,000 USPU] in alkalinized buffer), administered as a single dose via intravesical instillation; n=45 (anticipated)	Drug: VNX001; VNX001 (alkalinized lidocaine HCl and heparin sodium); Other Names: Alkalinized lidocaine HCl and heparin sodium
Placebo Comparator: Placebo; Alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)	Drug: Placebo; Inactive placebo for VNX001; Other Names: Placebo (for VNX001)
Experimental: Lidocaine; Lidocaine HCl (200 mg) in alkalinized buffer, administered as a single dose via intravesical instillation; n=45 (anticipated)	Drug: Lidocaine; Alkalinized lidocaine hydrochloride; Other Names: Alkalinized lidocaine HCl
Experimental: Heparin; Heparin sodium (50,000 USPU) in alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)	Drug: Heparin; Alkalinized heparin sodium; Other Names: Alkalinized heparin sodium

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sum of bladder pain intensity differences from baseline to 12 hours post-dose (SPID-12)	A measure of the sum of bladder pain intensity differences from baseline to 12 hours post-dose (SPID-12), as determined using an 11-point numerical rating scale (NRS) for bladder pain. The 11-point NRS for bladder pain is a scale from 0 to 10, with 0 indicating no bladder pain and 10 indicating the worst imaginable bladder pain.	12 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Use of optional open-label intravesical administration of VNX001	Number of patients requesting the optional open-label intravesical administration of VNX001 at 24-48 hours after randomized study drug administration	48 hours
Adverse events (AEs)	Incidence of treatment-emergent adverse events (TEAEs), drug-related adverse events (AEs), and discontinuations due to AEs	72 hours
Sum of bladder pain intensity differences from baseline to 6, 10, and 24 hours post-dose (SPID-6, SPID-10, and SPID-24, respectively)	A measure of the sum of bladder pain intensity differences from baseline to 6, 10, and 24 hours post-dose (SPID-6, SPID-10, and SPID-24, respectively), as determined using an 11-point numerical rating scale (NRS) for bladder pain. The 11-point NRS for bladder pain is a scale from 0 to 10, with 0 indicating no bladder pain and 10 indicating the worst imaginable bladder pain.	6, 10, or 24 hours
Change in bladder pain from baseline to 1, 4, 8, 12, and 24 hours post-dose	Average absolute change and average percentage change in bladder pain from baseline to 1, 4, 8, 12, and 24 hours post-dose, as determined using an 11-point numerical rating scale (NRS) for bladder pain. The 11-point NRS for bladder pain is a scale from 0 to 10, with 0 indicating no bladder pain and 10 indicating the worst imaginable bladder pain.	1, 4, 8, 12, and 24 hours
Change in Question 3 of the Patient Overall Rating of Improvement of Symptoms (PORIS) questionnaire	Percentage of subjects achieving ≥ 50% improvement in Question 3 of the PORIS questionnaire at 1, 10, and 24 hours post-dose. The PORIS questionnaire is an assessment of the subject's condition after treatment compared to before treatment. In particular, Question 3 of the PORIS questionnaire asks subjects to select the category that best describes the overall change in their condition compared to before receiving study medication; the choices are: worse, no better (0% improvement), slightly improved (25% improvement), moderately improved (50% improvement), greatly improved (75% improvement), or symptoms gone (100% improvement).	1, 10, and 24 hours

Collaborators and Investigators

• Sponsor: Vaneltix Pharma, Inc.
• Collaborators: Prevail Infoworks

Publications and helpful links

Helpful Links

• ENGAGE2024 Study Website

Study record dates

Study Major Dates

• Study Start (Actual): May 22, 2023
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026

Study Registration Dates

• First Submitted: February 10, 2023
• First Submitted That Met QC Criteria: February 10, 2023
• First Posted (Actual): February 21, 2023

Study Record Updates

• Last Update Posted (Actual): January 22, 2026
• Last Update Submitted That Met QC Criteria: January 21, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: heparin; intravesical; interstitial cystitis (IC); bladder pain syndrome (BPS); alkalinized lidocaine; VNX001
• Additional Relevant MeSH Terms: Urogenital Diseases; Male Urogenital Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urinary Bladder Diseases; Cystitis; Cystitis, Interstitial; Organic Chemicals; Carbohydrates; Anilides; Amides; Aniline Compounds; Amines; Acetanilides; Glycosaminoglycans; Polysaccharides; Lidocaine; Heparin
• Other Study ID Numbers: VNX001-111; Engage 2024

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No